ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Trials evaluating BCR-ABL TKIs in patients with CML have enrolled participants with a history of cardiovascular disease but, when cardiac endpoints were reported, these patients were not analyzed as a separate group (12).